Patent ID: 9662394
Date: 2017-05-30
CPC Classifications: A61K,A61P

Claim:
1. A composition comprising about 8% to about 12% efinaconazole by weight, water, C12-15 alkyl lactate, diisopropyl adipate, cyclomethicone, ethanol, butylated hydroxytoluene (BHT), a salt of ethylenediaminetetraacetic acid (EDTA), and citric acid, wherein the amount of BHT is in the range of about 0.01% (w/w) to about 2% (w/w), wherein the amount of the salt of EDTA is in the range of about 0.0001% (w/w) to about 1.5% (w/w), wherein the amount of citric acid is in the range of about 0.05% (w/w) to about 0.25% (w/w), wherein the composition is formulated as a solution, and wherein the amounts of BHT and the salt of EDTA are sufficient to ensure the composition is (i) colorless upon initial formulation and (ii) colorless or pale yellow after storage for three weeks at a temperature of about 40° C.